Showing 2631-2640 of 4112 results for "".
- Cutera Update: Agreements Made With Pura Vida and RTW; New Board Members Appointedhttps://practicaldermatology.com/news/cutera-update-agreements-made-with-pura-vida-and-rtw-new-board-members-appointed/2461712/Cutera announced that it has entered into cooperation agreements with two of its largest stockholders, Pura Vida Investments LLC and RTW Investments LP, which collectively own more than 15% of the company’s outstanding shares. Pursuant to the agreements, Cutera will appo
- DermTech Appoints Bret Christensen as New President and CEOhttps://practicaldermatology.com/news/dermtech-appoints-bret-christensen-as-new-president-and-ceo/2461707/DermTech announced the appointment of Bret Christensen as president, chief executive officer, and a member of the board of directors. Mr. Christensen, who was previously chief commercial officer of Insulet, succeeds Dr. John Dobak, who stepped down as president, CEO and a dir
- Online Exclusive: New Practice-changing Research Links ARD to Bacteriahttps://practicaldermatology.com/news/online-exclusive-new-practice-changing-research-links-rad-to-bacteria/2461701/As many as 95% of people undergoing radiation treatment for cancer will develop acute radiation dermatitis (ARD). Little, however, has been known about why this condition occurs, and there are no widely adapted or standardized treatments for preventing severe ARD. New research may chang
- Dr. Suneel Chilukuri Named Hydrinity Accelerated Skin Science’s Chief Medical Advisorhttps://practicaldermatology.com/news/dr-suneel-chilukuri-named-hydrinity-accelerated-skin-sciences-chief-medical-advisor/2461692/Suneel Chilukuri, MD, is Hydrinity Accelerated Skin Science’s new Chief Medical Advisor. In this role, Dr. Chilukuri will chair the Hydrinity Accelerated Skin Science Medical Advisory Board. He will aid product development as well as develop and oversee all clinica
- Opzelura Helps Beat AD Itchhttps://practicaldermatology.com/news/opzelura-helps-beat-ad-itch/2461690/Opzelura (ruxolitinib) cream 1.5% showed substantial and rapid itch reduction in patients with mild-moderate Atopic Dermatitis (AD). These data were featured in a poster presentation at the Revolutionizing Atopic Dermatitis (RAD) Conference, held from April 29-May 1 in Washing
- Lilly's Lebrikizumab Improves AD on Face, Handshttps://practicaldermatology.com/news/lillys-lebrikizumab-improves-ad-on-face-hands/2461689/Up to 73% of atopic dermatitis patients (AD) receiving lebrikizumab showed Improved or cleared skin on face or hands at 16 weeks, a new study shows. Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients 12 y
- New Class of Immunotherapy Drugs May Fight Melanomahttps://practicaldermatology.com/news/new-class-of-immunotherapy-drugs-may-fight-melanoma/2461682/A new class of immunotherapy shows promising results for fighting melanoma, a new study shows. The study, published in Nature Communications by researchers from King’s College London and Guy’s and St Thomas’ NHS Foundation Trust, investigates whether a n
- Maintaining Normal Vitamin D Levels May Benefit Melanoma Patients on Immunotherapyhttps://practicaldermatology.com/news/maintaining-normal-vitamin-d-levels-may-benefit-melanoma-patients-on-immunotherapy/2461677/Patients with advanced skin cancer should make extra efforts to maintain normal vitamin D levels when receiving immune checkpoint inhibitors, according to a study in
- Cynosure Taps New CEOhttps://practicaldermatology.com/news/cynosure-taps-new-ceo/2461676/Nadav Tomer is Cynosure’s new chief executive officer, effective May 1, 2023. He succeeds Todd Tillemans, who will step down and will work closely with Mr. Tomer to ensure a smooth transition. "Nadav has an incredibly strong track record of operation
- Galderma Survey Debunks Filler Mythshttps://practicaldermatology.com/news/galderma-survey-debunks-filler-myths/2461668/Forty percent of people say they would discourage others from using facial injectables to reduce wrinkles or provide volume, and 34% said they believed the results of such treatments look fake and unnatural, according to a new poll sponsored by Galderma. Despite these views, the same re